A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

523

Participants

Timeline

Start Date

May 2, 2018

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2027

Conditions
Advanced/Metastatic Solid TumorsColorectal CancerGastric CancerGastroesophageal-junction CancerNSCLCHNSCCHead and Neck Squamous Cell CarcinomaEsophageal Cancer
Interventions
DRUG

MCLA-158

full-length IgG1 bispecific antibody targeting EGFR and LGR5

COMBINATION_PRODUCT

MCLA-158 + Pembrolizumab

MCLA-158 in combination with pembrolizumab will be explored first in HNSCC patients eligible to receive pembrolizumab as first-line monotherapy.

COMBINATION_PRODUCT

MCLA-158 + FOLFIRI

MCLA-158 in combination with FOLFIRI will be explored in mCRC patients with up to 1 line of prior regimen.

COMBINATION_PRODUCT

MCLA-158 + FOLFOX

MCLA-158 in combination with FOLFOX will be explored in mCRC patients with up to 1 line of prior regimen.

Trial Locations (45)

13057

RECRUITING

Hematology-Oncology Associates of Central New York, Syracuse

14850

RECRUITING

Cayuga Medical Center, Ithaca

24014

RECRUITING

Oncology & Hematology Associates of Southwest Virginia, Roanoke

32827

RECRUITING

Sarah Cannon Research Institute (Lake Nona), Orlando

33901

RECRUITING

Florida Cancer Specialists, Fort Myers

37203

COMPLETED

Sarah Cannon Research Institute, Nashville

38103

RECRUITING

The University Of Tennessee Health Science Center, Memphis

43537

RECRUITING

Taylor Cancer Research Center, Maumee

44195

RECRUITING

Cleveland Clinic, Cleveland

63110

RECRUITING

SSM Health Saint Louis University Hospital, St Louis

RECRUITING

Washington University School of Medicine at St Louis, St Louis

73102

RECRUITING

SSM OKC Hightower Clinical, Oklahoma City

75246

RECRUITING

Texas Oncology, Dallas

75702

RECRUITING

Texas Oncology, Tyler

77030

RECRUITING

Oncology Consultants, Houston

80124

RECRUITING

Rocky Mountain Cancer Centers, Lone Tree

84106

RECRUITING

Utah Cancer Specialists, Salt Lake City

84112

RECRUITING

University of Utah Health Huntsman Cancer Hospital, Salt Lake City

90033

RECRUITING

USC Norris Comprehensive Cancer Center, Los Angeles

92093

RECRUITING

UCSD, La Jolla

92123

RECRUITING

Sharp Healthcare, San Diego

99202

RECRUITING

Cancer Care Northwest, Spokane

02114

RECRUITING

Massachusetts General Hospital - Dana Farber, Boston

Unknown

RECRUITING

Cliniques universitaires Saint-Luc, Brussels

RECRUITING

Institut Jules Bordet, Brussels

RECRUITING

UZ Gent, Ghent

RECRUITING

Chu Ucl Namur Site De Sainte-Elisabeth, Namur

RECRUITING

Hopital Saint Andre, CHU Bordeaux, Bordeaux

RECRUITING

Centre Leon Berard, Lyon

RECRUITING

Hopital La Timone, Marseille

RECRUITING

Institut Régional du Cancer de Montpellier, Montpellier

RECRUITING

Centre Antoine Lacassagne, Nice

RECRUITING

Institut Curie, Paris

RECRUITING

Institut Gustave Roussy, Paris

RECRUITING

Centre Henri Becquerel, Rouen

RECRUITING

NKI - Antoni van Leeuwenhoek, Amsterdam

RECRUITING

UMC Radboud, Nijmegen

RECRUITING

UMC Utrecht, Utrecht

RECRUITING

Vall d'Hebron, Barcelona

RECRUITING

Hospital 12 de Octubre, Madrid

RECRUITING

Clinica Universidad de Navarra, Pamplona

RECRUITING

Hospital Universitario de Navarra, Pamplona

RECRUITING

Instituto Valenciano de Oncologia, Valencia

COMPLETED

Cambridge University Hospitals NHS Foundation Trust, Cambridge

RECRUITING

Sarah Cannon Research Institute, London

All Listed Sponsors
lead

Merus N.V.

INDUSTRY